<code id='67F5675E3C'></code><style id='67F5675E3C'></style>
    • <acronym id='67F5675E3C'></acronym>
      <center id='67F5675E3C'><center id='67F5675E3C'><tfoot id='67F5675E3C'></tfoot></center><abbr id='67F5675E3C'><dir id='67F5675E3C'><tfoot id='67F5675E3C'></tfoot><noframes id='67F5675E3C'>

    • <optgroup id='67F5675E3C'><strike id='67F5675E3C'><sup id='67F5675E3C'></sup></strike><code id='67F5675E3C'></code></optgroup>
        1. <b id='67F5675E3C'><label id='67F5675E3C'><select id='67F5675E3C'><dt id='67F5675E3C'><span id='67F5675E3C'></span></dt></select></label></b><u id='67F5675E3C'></u>
          <i id='67F5675E3C'><strike id='67F5675E3C'><tt id='67F5675E3C'><pre id='67F5675E3C'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:7299
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          What drug price negotiations mean for Medicare Part D
          What drug price negotiations mean for Medicare Part D

          AdobeAftertherecentannouncementofthefirst10drugsselectedforMedicarepricenegotiation,muchhasbeendiscu

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Why Novartis is changing the name of its research labs

          FionaMarshall,presidentoftheNovartisresearchhubinCambridge,Mass.,speaksThursdayduringtheSTATFutureSu